Intercell losses rise in second quarter
Vienna – Austrian vaccine specialist Intercell AG increased R&D spending by 24% in the second quarter of 2010 to EUR16.9m due to expenditures linked to clinical Phase III testing of its traveller's diarrhoea vaccine. That increased the group’s net loss to EUR8.3m compared to EUR3.1m over the same period last year. Group sales decreased to around EUR9.7m due to lower revenues from collaborations and licensing agreements. However, sales of Intercell’s vaccine against Japanese encephalitis (Ixiaro) rose to EUR5.2m, up from EUR2.4m in the same period in 2009.